>
Arrowhead Pharmaceuticals Inc logo

ARWR - Arrowhead Pharmaceuticals Inc Share Price

$67.65 -0.3  -0.5%

Last Trade - 16/04/21

Sector
Healthcare
Size
Large Cap
Market Cap £5.08bn
Enterprise Value £4.86bn
Revenue £57.7m
Position in Universe 1152nd / 6850
Bullish
Bearish
Unlock ARWR Revenue
Momentum
Relative Strength (%)
1m -12.5%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -26.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Sep 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.38 0.16 31.4 16.1 168.8 88.0 137.3 219.7 +196.8%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 December 2020,Arrowhead Pharmaceuticals Inc revenues decreased 28% to$21.3M. Net loss increased from $2.7M to $20.7M. Revenuesreflect a decrease in demand for the Company's products andservices due to unfavorable market conditions. Higher netloss reflects Research and development - Balancing valincrease of 57% to $34.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ARWR Revenue Unlock ARWR Revenue

Net Income

ARWR Net Income Unlock ARWR Revenue

Normalised EPS

ARWR Normalised EPS Unlock ARWR Revenue

PE Ratio Range

ARWR PE Ratio Range Unlock ARWR Revenue

Dividend Yield Range

ARWR Dividend Yield Range Unlock ARWR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ARWR EPS Forecasts Unlock ARWR Revenue
Profile Summary

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Directors
Last Annual September 30th, 2020
Last Interim December 31st, 2020
Incorporated February 13, 2001
Public Since December 14, 1993
No. of Shareholders: 106
No. of Employees: 98
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P 400 Mid Cap , Nasdaq Composite , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 103,792,410
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ARWR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ARWR
Upcoming Events for ARWR
Tuesday 4th May, 2021
Q2 2021 Arrowhead Pharmaceuticals Inc Earnings Release
Tuesday 4th May, 2021
Q2 2021 Arrowhead Pharmaceuticals Inc Earnings Call
Tuesday 3rd August, 2021 Estimate
Q3 2021 Arrowhead Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Arrowhead Pharmaceuticals Inc
What is the Arrowhead Pharmaceuticals Inc share price?

As of 16/04/21, shares in Arrowhead Pharmaceuticals Inc are trading at $67.65, giving the company a market capitalisation of £5.08bn. This share price information is delayed by 15 minutes.

How has the Arrowhead Pharmaceuticals Inc share price performed this year?

Shares in Arrowhead Pharmaceuticals Inc are currently trading at $67.65 and the price has moved by 94.23% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arrowhead Pharmaceuticals Inc price has moved by 33.88% over the past year.

What are the analyst and broker recommendations for Arrowhead Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Arrowhead Pharmaceuticals Inc, there are there are currently 2 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Arrowhead Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Arrowhead Pharmaceuticals Inc next release its financial results?

Arrowhead Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Arrowhead Pharmaceuticals Inc dividend yield?

Arrowhead Pharmaceuticals Inc does not currently pay a dividend.

Does Arrowhead Pharmaceuticals Inc pay a dividend?

Arrowhead Pharmaceuticals Inc does not currently pay a dividend.

When does Arrowhead Pharmaceuticals Inc next pay dividends?

Arrowhead Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Arrowhead Pharmaceuticals Inc shares?

To buy shares in Arrowhead Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Arrowhead Pharmaceuticals Inc?

Shares in Arrowhead Pharmaceuticals Inc are currently trading at $67.65, giving the company a market capitalisation of £5.08bn.

Where are Arrowhead Pharmaceuticals Inc shares listed? Where are Arrowhead Pharmaceuticals Inc shares listed?

Here are the trading details for Arrowhead Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ARWR
What kind of share is Arrowhead Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Arrowhead Pharmaceuticals Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Arrowhead Pharmaceuticals Inc share price forecast 2021?

Shares in Arrowhead Pharmaceuticals Inc are currently priced at $67.65. At that level they are trading at 34.77% discount to the analyst consensus target price of 0.00.

Analysts covering Arrowhead Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.523 for the next financial year.

How can I tell whether the Arrowhead Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arrowhead Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 12.57%. At the current price of $67.65, shares in Arrowhead Pharmaceuticals Inc are trading at 9.95% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Arrowhead Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Arrowhead Pharmaceuticals Inc.

Who are the key directors of Arrowhead Pharmaceuticals Inc?

Arrowhead Pharmaceuticals Inc's management team is headed by:

Christopher Anzalone - CEO
Kenneth Myszkowski - CFO
Mauro Ferrari - IND
Douglass Given - CHM
Michael Perry - LED
Patrick O'Brien - CCO
William Waddill - IND
Javier San Martin - OTH
Curt Bradshaw - CSO
Marianne De Backer - IND
James Hassard - OTH
Oye Olukotun - IND
James Hamilton - SVP
Who are the major shareholders of Arrowhead Pharmaceuticals Inc?

Here are the top five shareholders of Arrowhead Pharmaceuticals Inc based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 10.89% (11.3m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.94% (9.28m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 3.79% (3.93m shares)
Johnson & Johnson Innovation-JJDC, Inc. Venture Capital
Percentage owned: 3.14% (3.26m shares)
Invesco Advisers, Inc. Investment Advisor
Percentage owned: 2.96% (3.08m shares)
Similar to ARWR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.